Clinical trial
Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study
NCT02096965 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- November 30, 2015
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nephrolithiasis, calcium oxalate, nephrolithiasis, calcium phosphate